Preprint Brief Report Version 1 Preserved in Portico This version is not peer-reviewed

Glycemia and New-onset Diabetes among COVID-19 Patients with Prediabetes: A Follow-up Study in India

Version 1 : Received: 18 November 2022 / Approved: 22 November 2022 / Online: 22 November 2022 (10:39:38 CET)

A peer-reviewed article of this Preprint also exists.

Chandrasekaran, N.D.; Sathish, T. Glycemia and New-Onset Diabetes among COVID-19 Patients with Prediabetes: A Follow-Study of Case Series in India. Diabetology 2023, 4, 19-27. Chandrasekaran, N.D.; Sathish, T. Glycemia and New-Onset Diabetes among COVID-19 Patients with Prediabetes: A Follow-Study of Case Series in India. Diabetology 2023, 4, 19-27.

Abstract

Studies have shown that COVID-19 patients with prediabetes frequently present with high plasma glucose levels on hospital admission. However, whether the glycemic abnormalities are temporary or persist after recovery from the illness is unclear. We conducted a prospective cohort study of 69 COVID-19 patients with prediabetes (HbA1c 5.7-6.4%) who were admitted to a tertiary care hospital in Chennai, India, from May to October 2020 and were discharged alive. Over a mean follow-up of 146.6 (SD: 72.5) days, the mean fasting plasma glucose rose by 16.8 mg/dl (from 119.3-136.1 mg/dl), 2-hr post-prandial glucose by 61.0 mg/dl (from 176.2-237.2 mg/dl), and HbA1c by 0.6% (5.9-6.5%). Of the 49 (84.5%) patients who were discharged with glucose-lowering medications, 40 (81.6%) continued taking them at the first follow-up visit (mean of 50.1 days from admission), and 39 (79.6%) continued taking them at the second follow-up visit (mean of 114.3 days from first the follow-up visit). In addition, 12.1% of patients developed new-onset diabetes after recovery from the illness. Continuous monitoring of glycemia and detecting new-onset diabetes in COVID-19 patients with prediabetes after recovery are essential, as the metabolic effects of SARS-CoV-2 persist for several months.

Keywords

coronavirus disease 2019; COVID-19; severe acute respiratory syndrome coronavirus 2; SARS-CoV-2, prediabetes; new-onset diabetes; diabetes; HbA1c; long COVID

Subject

Medicine and Pharmacology, Endocrinology and Metabolism

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.